

RESEARCH ARTICLE

Subfertility and Risk of Testicular Cancer in the EPSAM Case-Control Study

Chiara Grasso^{1*}, Daniela Zugna¹, Valentina Fiano¹, Nena Robles Rodriguez¹, Milena Maule¹, Anna Gillio-Tos¹, Libero Ciuffreda², Patrizia Lista², Nereo Segnan³, Franco Merletti¹, Lorenzo Richiardi¹

1 Cancer Epidemiology Unit-CeRMS, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy, **2** Medical Oncology Division 1, University Hospital "Città della Salute e della Scienza", Turin, Italy, **3** Department of Cancer Screening and Unit of Cancer Epidemiology, WHO Collaborative Center for Cancer Early Diagnosis and Screening, CPO Piedmont and University Hospital "Città della Salute e della Scienza", Turin, Italy

* chgrasso@unito.it



Abstract

OPEN ACCESS

Citation: Grasso C, Zugna D, Fiano V, Robles Rodriguez N, Maule M, Gillio-Tos A, et al. (2016) Subfertility and Risk of Testicular Cancer in the EPSAM Case-Control Study. PLoS ONE 11(12): e0169174. doi:10.1371/journal.pone.0169174

Editor: Thomas Behrens, Ruhr-Universität Bochum, GERMANY

Received: July 22, 2016

Accepted: December 13, 2016

Published: December 30, 2016

Copyright: © 2016 Grasso et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was partially supported by the Piedmont Region (www.regione.piemonte.it). NRR was funded by a scholarship Erasmus Columbus project for academic mobility scholarships in the thematic fields related to health and public health (ERACOL) (<http://nihes.com/eracol>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Background/objectives

It has been suggested that subfertility and testicular cancer share genetic and environmental risk factors. We studied both subfertility and the strongest known testicular cancer susceptibility gene, the c-KIT ligand (KITLG), whose pathway is involved in spermatogenesis.

Methods

The EPSAM case-control study is comprised of testicular cancer patients from the Province of Turin, Italy, diagnosed between 1997 and 2008. The present analysis included 245 cases and 436 controls from EPSAM, who were aged 20 years or older at diagnosis/recruitment. The EPSAM questionnaire collected information on factors such as number of children, age at first attempt to conceive, duration of attempt to conceive, use of assisted reproduction techniques, physician-assigned diagnosis of infertility, number of siblings, and self-reported cryptorchidism. Genotyping of the KITLG single nucleotide polymorphism (SNP) rs995030 was performed on the saliva samples of 202 cases and 329 controls.

Results

Testicular cancer was associated with the number of children fathered 5 years before diagnosis (odds ratio (OR) per additional child: 0.78, 95% confidence interval (CI): 0.58–1.04) and sibship size (OR per additional sibling: 0.76, 95% CI: 0.66–0.88). When considering the reproductive history until 1 year before diagnosis, attempting to conceive for at least 12 months or fathering a child using assisted reproduction techniques was not associated with the risk of testicular cancer, nor was age at first attempt to conceive or physician-assigned diagnosis of infertility. The SNP rs995030 was strongly associated with risk of testicular cancer (per allele OR: 1.83; 95%CI: 1.26–2.64), but it did not modify the association between number of children and the risk of testicular cancer.

Competing Interests: The authors have declared that no competing interests exist.

Conclusion

This study supports the repeatedly reported inverse association between number of children and risk of testicular cancer, but it does not find evidence of an association for other indicators of subfertility.

Introduction

Testicular cancer is a relatively rare malignancy and occurs most commonly in young and middle-aged men [1, 2]. Although the incidence of testicular cancer is low worldwide, over the last decades it has increased by 3–4% per year in several populations [3]. There are few well-established risk factors for testicular cancer, including cryptorchidism, contralateral testicular cancer, family history of testicular cancer, and height [4]. Ninety-five percent of testicular cancers are germ cell tumours, which can be subcategorized into seminomas and nonseminomas.

There is a large amount of literature on the association between subfertility and the risk of testicular cancer. Large register-based studies in the Nordic countries found that men with testicular cancer fathered fewer children before their diagnosis than did their corresponding control populations [5–7], and this association has been replicated in other case-control studies [8–10]. Furthermore, men with testicular cancer tend to have fewer siblings, which might suggest a reduced fertility in their parents [11–13].

The associations between the risk of testicular cancer and other questionnaire-based indicators of infertility (e.g. difficulty impregnating a partner or reported diagnosis of infertility) and clinical measures of infertility (e.g. sperm count and motility, serum Inhibin B, FSH, and testosterone) are less consistent and more difficult to investigate than the number of children fathered, due to problems of reverse causation, measurement errors, and recall and detection bias. Cohort studies of men evaluated for infertility [14–19] have found an increased risk of testicular cancer among those with abnormal semen analyses or male-factor infertility. These studies have the strength of prospective measurements of fertility, often using semen analysis, but they may be affected by other sources of bias, including confounding by cryptorchidism, and detection bias. Furthermore, couples seeking medical advice for fertility problems are a selected sample, whose data might not be comparable with population-based external cancer incidence data.

Malignancies of the testis have an important inherited component: brothers and sons of testicular cancer patients have an 8–10 and 4–6 fold increased risk of testicular cancer, respectively [20].

Genome-wide association studies (GWAS) have detected more than twenty loci that are associated with the risk of testicular cancer [21–28]. Notably, two independent GWAS found that allele variations in KITLG (the unique ligand for the receptor tyrosine kinase KIT) were the strongest genetic risk factors for testicular germ cell tumors [21, 22]. These studies showed that the KITLG single nucleotide polymorphism (SNP) rs995030 was associated with an at least 2-fold increased risk of testicular cancer. The other identified SNPs were in strong linkage disequilibrium with each other and with rs995030 ($r^2 > 0.8$), which may thus serve as a TagSNP. Apart from these SNPs, other genetic alterations of the KIT/KITLG pathway have been linked to an increased susceptibility to testicular germ cell tumors [29–33].

The KIT–KITLG system is also crucial for germ cell survival, proliferation, motility, and migration [34], and its alterations may impair fertility. Indeed, mutations [35, 36], complete or partial deletions of KIT or KITLG sequences [37, 38] and altered expression of either genes

have been reported to be involved in the disruption of normal germ cell development [39, 40], in increased spermatocyte apoptosis [41], and in microenvironment alterations [42].

A few epidemiological studies found some empirical evidence of an association between KIT/KITLG SNPs and the risk of male infertility, although the results were not entirely consistent [43–45].

We used data from the EPSAM case-control study, carried out in the North of Italy, to estimate the role of subfertility in the aetiology of testicular cancers. In order to disentangle the possible roles of shared environmental and genetic risk factors, we also assessed interactions the KITLG SNP rs995030 may have with subfertility in its association with the risk of testicular cancer.

Material and Methods

The EPSAM study was approved by the Ethical Committee (IRB) of the San Giovanni Battista Hospital–CTO/CRF/Maria Adelaide Hospital (Turin, Italy). All individual participants included in the study signed informed consent forms.

The EPSAM study

The EPSAM case-control study is comprised of patients resident in the Province of Turin, Italy diagnosed with a histologically-confirmed testicular germ cell tumor between 1997 and 2008 and their controls.

Testicular germ cell cancer cases who underwent an orchiectomy (ICD-9 CM surgical procedure codes: 623–624) for testicular cancer (ICD-9 CM diagnostic code: 186) during the study period were identified in regional Hospital Discharge Registry. Those patients who were treated at the Oncology Ward of the San Giovanni Battista Hospital (the main hospital of the city of Turin) were contacted through their oncologist; patients who were treated at other hospitals were contacted through their GPs (81% of the contacted GPs with eligible patients agreed to collaborate). Histological reports of all cases were consulted to determine the subtype of the germ cell tumors (seminoma or nonseminoma). One case without histological confirmation was included in the study on the basis that 95% of testicular tumors are germ cell cancers.

Up to two population-based controls were selected per case: for each case contacted through his GP, we randomly selected two men from the list of the same GP, matched by year of birth and residence (Turin or rest of the province of Turin), and for each case contacted through the San Giovanni Battista Hospital, we contacted up to two patients frequency matched by birth year and residence among patients admitted at the same hospital for non-neoplastic diseases that were unrelated to hormonal factors, fertility status, or testicular health.

All cases and controls completed a questionnaire that collected information on age at diagnosis, exposures occurring during puberty, adolescence, and early adulthood, as well as on main risk factors for testicular cancer. This included year of birth, residence, and education level, as well as detailed information on fertility: number of children, information on each child fathered, including date of birth, age at first attempt to conceive, duration of attempts to conceive, use of assisted reproduction techniques, number of months of attempts to conceive and if they ever visiting a doctor for infertility problems, physician-assigned diagnosis of male- or female-factor infertility, number of siblings (which was used to calculate sibship size), and self-reported cryptorchidism. The response proportion was 57% among cases and 48% among controls.

Cases and controls were also asked to self-collect and mail a saliva sample using the Oragene DNA (OG-250) Collection Kit (DNA Genotek Inc., Ottawa, Canada), with a response proportion of 84% among both cases and controls.

Full details of the EPSAM study design have been described in previous publications [46, 47]. Anonymized data on fertility status and genotyping of cases and controls are available upon request to qualified researchers for the purpose of academic, non-commercial research.

Study sample

For the purposes of this analyses, we restricted the study sample to participants born in Italy (5 cases and 6 controls excluded) and aged at least 20 years at diagnoses/recruitment (15 cases and 31 controls excluded), as it is unlikely that attempts to conceive happen before this age. This left 245 cases 436 controls in the analytical sample. Genotyping of the KITLG single nucleotide polymorphism (SNP) rs995030 was performed on the saliva samples of 202 cases and 342 controls.

Molecular analyses

DNA was extracted from 1 ml of saliva using the Oragene Purifier solution (OG-L2P) following manufacturer's protocol. The β -globin gene fragment (268 bp) was amplified by PCR using previously published conditions [48] and analyzed in 2% agarose-gel electrophoresis. One case and 15 controls were excluded from genotyping due to DNA inadequacy.

Genotyping of the SNP rs995030 within the 3'UTR of the KITLG gene (Chromosome 12, NCBI Nucleotide Reference Sequence: NG_012098.1) was performed. Primers, designed using the PyroMark Assay Design software version 2.0 (Qiagen, Hilden, Germany) were: 5' -ACTG TGAAGACTGGCACTGAATTAA-3' (forward), 5' -BIOT-CTTGCAGAGACCAGGATAACTAC A-3' (reverse), 5' -CGTGTCTCAGACTGCAT-3' (sequencing). PCR was carried out in a final volume of 35 μ l containing 20 ng of genomic DNA, 1X PCR Gold Buffer, 1.5 mM MgCl₂ (Applied Biosystems, Foster City, CA), 0.8 mM dNTPs mix (Promega, Madison, WI, USA), 0.5 μ mol of each amplification primer (Sigma Aldrich, St. Louis, MO, USA) and 0.05 U of AmpliTaq Gold DNA polymerase (Applied Biosystems). The PCR termic profile was: denaturation at 95°C (10 min) followed by 45 cycles of 95°C (30 s), 60°C (1 min), 72°C (1 min), and a final extension step at 72°C (10 min). Pyrosequencing analysis was performed onto a PyroMark Q24 MDx Pyrosequencing System (Qiagen).

Statistical analyses

Information on fertility from questionnaires was used to create indicators of fertility. First, we analyzed the number of children fathered by cases and controls before diagnosis of testicular cancer (for controls a reference age was randomly assigned on the basis of the age distribution at diagnosis of the cases). We then analyzed the age at first attempt to conceive, irrespective of its success. This is a potential confounder of the association between number of children and risk of testicular cancer, because earlier age at first attempt gives more opportunities to conceive in analyses that are restricted to the period before cancer diagnosis, and thus cannot cover the entire reproductive period, and because fertility declines with age. As a more direct assessment, we also constructed a combined indicator of fertility based on the duration of attempts to conceive for men whose attempts were successful and for those whose attempts were not: (1) had children without attempting to conceive or after attempting for less than 12 months; (2) did not have children and did not attempt to conceive; (3) attempted to conceive for at least 12 months and had/did not have children or had children using assisted reproduction techniques.

When calculating the number of children fathered, we introduced lag-times before testicular cancer diagnosis (reference age for controls) of 1 year and 5 years to increase the study's

comparability with other studies. For the other indicators of fertility we used a lag-time of 1 year.

We used unconditional logistic regression to estimate odds ratios (ORs) with corresponding 95% confidence intervals (CIs) of testicular cancer, adjusting for matching variables—year of birth, residence (city of Turin, rest of the Province of Turin), method of recruitment (GPs or hospital oncologist)—as well as for age at diagnosis/reference age, educational level (junior high school, high school, university degree), and cryptorchidism. Analyses on age at first attempt to conceive were restricted to cases and controls who attempted to conceive before the diagnosis of testicular cancer or the reference age for controls.

We performed sensitivity analyses to check for possible biases in the analyses on fertility. First, we restricted the analysis to subjects who did not report cryptorchidism, and second to cases and controls aged at least 35, who have a more complete reproductive history.

For the analyses on the KITLG SNP rs995030, we first tested for the Hardy-Weinberg equilibrium (HWE) among controls. We used unconditional logistic regression to estimate the OR of testicular cancer for each genotype according to the codominant model, as well as the OR for each allele according to an additive model.

We also performed stratified analyses by histological subtype (seminoma or nonseminoma histology). Stata software version 12.0 (Stata Corporation, College Station, Texas) was used for the analyses.

Results

Characteristics of the 245 testicular cancer cases and 436 controls included in this study are summarized in [Table 1](#). Cases and controls had similar educational levels while cryptorchidism was, as expected, more frequent among cases. Of the 245 cases, 136 had seminoma and 108 had nonseminoma histology.

As reported in [Table 2](#), we observed an inverse association with risk of testicular cancer for number of children fathered by testicular cancer cases, although CIs were large (OR: 0.78, 95% CI: 0.58–1.04, per child when a 5-year lag-time was considered). Sibship size of the cases was also inversely associated with risk of testicular cancer (OR: 0.76, 95% CI: 0.66–0.88, per sibling). Age at first attempt to conceive was not associated with the risk of testicular cancer, and remarkably, there was no evidence of an association between our combined indicator of fertility (based on time to conception and use of assisted reproduction techniques) and risk of testicular cancer.

14 cases and 15 controls reported having visited a doctor for infertility problems up to 1 year before diagnosis/recruitment. After adjustment for cryptorchidism this rendered an OR of 1.32 (95% CI: 0.59–2.93), which increased to 1.88 (95% CI: 0.35–7.31) when the exposure was restricted to those reporting a physician-assigned diagnosis of infertility (11 cases and 11 controls) (data not shown). Adjustment for KITLG genotype did not substantially change these estimates (data not shown).

Restriction to patients without cryptorchidism and to patients diagnosed after 35 years of age altered the findings only marginally (data not shown). There was no substantial heterogeneity between the two histological subtypes, although the statistical power of the estimates was quite modest. Only when we considered the combined indicator of fertility and age at first attempt to conceive we observed different estimates and an opposite effect in the two histological subtypes; however the statistical power of these results was too weak to draw clear conclusions (See [Supporting information, S1 and S2 Tables](#)). We also tested the p-value for interaction between fertility indicators and histological type and we did not find evidence of heterogeneity between seminoma and nonseminoma (See [Supporting information, S3 Table](#)).

Table 1. Selected characteristics of cases and controls.

Characteristic	Cases (N = 245)		Controls (N = 436)	
	N	(%)	N	(%)
Year of birth				
<1960	47	19.2	101	23.2
1960–69	80	32.6	140	32.1
1970–79	100	40.8	165	37.8
1980+	18	7.4	30	6.9
Method of recruitment				
General Practitioners	163	66.5	300	68.8
Hospital	82	33.5	136	31.2
Residence				
City of Turin	95	38.8	189	43.3
Province of Turin	150	61.2	247	56.7
Education level				
Junior high school	90	36.7	154	35.4
High school	98	40.0	190	43.7
University degree	57	23.3	91	20.9
Missing	0		1	
Cryptorchidism^a				
No	203	87.9	401	96.9
Yes	28	12.1	13	3.1
Missing	14		22	
Histology				
Seminoma	136	55.7	-	
Nonseminoma	108	44.2	-	
Missing	1		-	

^a Self-reported physician-diagnosed cryptorchidism.

doi:10.1371/journal.pone.0169174.t001

Among subjects with saliva samples, genotyping of rs995030 was successful in 202 cases and 333 controls (genotyping success rate: 98.7%); there was no evidence of departure from HWE ($p = 0.10$) among controls. Homozygous status for the risk allele (CC) was associated with an OR of testicular cancer of 5.38 (95% CI 1.21–23.91), compared with the homozygous status for the non-risk minor allele (TT). Additive analyses revealed an OR of 1.83 (95% CI 1.26–2.64) per 1-copy increase of the C allele (Table 3).

The association between number of children fathered before diagnosis/reference age and risk of testicular cancer was not modified by KITLG genotype, categorised as CC vs. TT/CT (Table 4). Similarly, no evidence of effect modification was found for the combined indicator of fertility status (data not shown). Last, we performed the analyses, restricted to control subjects, on the association between the KITLG genotype and the measures of subfertility collected. We did not find evidence of an association for number of children fathered 1 year and 5 year before diagnosis/reference date, age at first attempt of having children and for sibship size, although an indication of an association between KITLG genotype (CC vs CT/TT) and attempting to conceive for at least 12 months or fathering a child using assisted reproduction techniques, compared with attempting to conceive for less than 12 months before having a child, could be noted (unadjusted OR: 2.75, 95% CI: 0.89–8.53) (data not shown in Tables).

Table 2. Association between indicators of fertility and risk of testicular cancer.

	N° of cases (%)	N° of controls (%)	OR1 ^a	95% CI ^a	OR2 ^a	95% CI ^a
Number of children 1 year before diagnosis/reference date						
0	146 (63.8)	242 (59.5)	1.00	Ref	1.00	Ref
1	47 (20.5)	77 (18.9)	1.05	0.66–1.67	1.10	0.68–1.77
≥2	36 (15.7)	88 (21.6)	0.74	0.43–1.27	0.79	0.46–1.37
Missing	2	6				
Unit increase			0.85	0.66–1.09	0.88	0.68–1.13
Number of children 5 years before diagnosis/reference date						
0	169 (73.8)	274 (67.3)	1.00	Ref	1.00	Ref
1	36 (15.7)	64 (15.7)	0.91	0.54–1.52	0.95	0.56–1.61
≥2	24 (10.5)	69 (17.0)	0.56	0.30–1.04	0.63	0.33–1.18
Missing	2	6				
Unit increase			0.74	0.55–0.98	0.78	0.58–1.04
Age at first attempt to conceive (years)^b						
<25	11 (19.0)	18 (18.4)	0.88	0.35–2.21	0.89	0.35–2.22
25–29	29 (50.0)	43 (43.9)	1.00	Ref	1.00	Ref
30–34	15 (25.9)	33 (33.7)	0.63	0.28–1.43	0.54	0.23–1.26
≥35	3 (5.2)	4 (4.1)	0.84	0.16–4.40	0.86	0.16–4.53
Unit increase			0.98	0.89–1.06	0.97	0.89–1.06
Combined indicator of fertility (1 year before diagnosis/reference date)						
Had children without attempting to conceive or attempting for less than 12 months	71 (31.6)	146 (37.0)	1.00	Ref	1.00	Ref
Did not have children and did not attempt to conceive	135 (60.0)	220 (55.7)	1.11	0.71–1.73	1.06	0.68–1.67
Attempted to conceive for at least 12 months and had or had not children, or had children using assisted reproduction techniques	19 (8.4)	29 (7.3)	1.28	0.67–2.45	1.04	0.53–2.05
Missing	6	18				
Sibship size						
1	59 (25.8)	74 (18.2)	1.00	Ref	1.00	Ref
2	105 (45.8)	174 (42.9)	0.71	0.46–1.09	0.72	0.46–1.11
≥3	65 (28.4)	158 (38.9)	0.52	0.33–0.83	0.54	0.34–0.86
Missing	2	7				
Unit increase			0.75	0.65–0.87	0.76	0.66–0.88

^a Adjusted for year of birth, residence (city of Turin, rest of the Province of Turin), method of recruitment (General Practitioners or hospital), age at diagnosis or reference age for controls, and educational level (junior high school, high school, university degree)

OR2 adjusted as OR1 and for cryptorchidism

^b Restricted to cases and controls who tried to have children at least 5 years before diagnosis or reference age for controls

OR, odds ratio; CI, confidence interval; Ref, reference

doi:10.1371/journal.pone.0169174.t002

Table 3. Association between the KITLG SNP rs995030 and testicular cancer.

Genetic model	Genotype or Allele	Cases (N = 202) (%)	Controls (N = 342) (%)	OR ^a	95% CI ^a
Codominant	TT	2 (1.0)	15 (4.5)	1.00	Ref
	CT	39 (19.3)	91 (27.3)	3.22	0.70–14.80
	CC	161 (79.7)	227 (68.2)	5.38	1.21–23.91
	Missing	0	9		
Additive (per allele)	C			1.83	1.26–2.64

^a Adjusted for year of birth, residence (city of Turin, rest of the Province of Turin), and method of recruitment OR, odds ratio; CI, confidence interval; Ref, reference

doi:10.1371/journal.pone.0169174.t003

Discussion

We used data from the EPSAM case-control study to explore the relation between subfertility and the risk of testicular cancer using questionnaire information on fecundity (i.e. number of children) and a combined indicator of fertility. We found an inverse association between the number of children fathered before cancer diagnosis and risk of testicular cancer, which was not explained by age at first attempt to conceive, as this variable was similar among cases and controls. Sibship size was inversely associated with the risk of testicular cancer. Conversely, we did not find an association between our combined indicator of fertility and risk of testicular cancer, although this indicator took into account at the same duration of attempt to conceive, unexpected pregnancies, and use of assisted reproduction techniques.

The association between fertility and testicular cancer has been investigated in a large number of studies. Number of children has consistently been reported to be associated with a decreased risk of testicular cancer both in questionnaire-based case-control studies [8–10] and in registry-based studies [5–7]. This association typically remains when analyses take into account socioeconomic factors or history of cryptorchidism, as in our study. Sibship size has also been repeatedly associated with a decreased risk of testicular cancer [11, 13].

Although our study is consistent with previous studies concerning number of children, we found no association between a combined indicator of fertility and risk of testicular cancer. If subfertility was actually associated with the development of testicular cancer, we would have expected to find a longer duration of attempt to conceive and/or an increased use of assisted reproduction techniques among cases compared to controls, but this was not observed.

Overall results from case-control studies using self-reported indicators of subfertility other than fecundity provide a conflicting picture [9, 10, 49–52]. Firstly, these studies are strongly heterogeneous: they used different indicators of subfertility and different, if any, lag-times

Table 4. Assessment of effect modification of KITLG on number of children fathered.

Genotype	Number of children 5 years before diagnosis	
	OR ^a	95% CI ^a
CT/TT	0.76	0.46–1.26
CC	0.74	0.53–1.02

^a Adjusted for year of birth, residence (city of Turin, rest of the Province of Turin), method of recruitment (GPs or hospital), age at diagnosis or reference age for controls, educational level (junior high school, high school, university degree), and cryptorchidism. OR, odds ratio, CI, confidence interval.

doi:10.1371/journal.pone.0169174.t004

between the age at assessment of the indicator and cancer diagnosis, and only some of them presented estimates adjusted for cryptorchidism. Indeed, most studies found that fertility problems are more frequent in cases than controls, but the magnitude of the estimates varied strongly and it was often impossible to exclude the possibility that reverse causation and/or confounding by cryptorchidism explained the reported effects.

Cohort studies with information on prospectively-obtained semen parameters have consistently found an association between impaired semen quality and risk of testicular cancer [14–19]. When the lag-time between semen analysis and cancer diagnosis was considered, the risk of testicular cancer seemed to be especially increased in the same year or in the year after semen analysis [5, 15], although it was also evident for longer lag times, indicating that the association was affected by reverse causation and/or detection bias to a certain extent. It is noteworthy that the magnitude of the associations was not dramatically large, and it is unclear if it could explain the inverse association between number of children fathered and risk of testicular cancer.

Overall, considering the evidence from register-based, case-control and cohort studies, it seems that the consistent, inverse associations between risk of testicular cancer and number of children and sibship size are not entirely paralleled or supported by the results of studies that tried to obtain more direct measurements of fertility.

Since heredity plays a strong role in testicular cancer, we performed genetic analyses to take this component into account. We did not test our samples for the *gr/gr* microdeletion on the Y chromosome, which is largely associated with impaired spermatogenesis [53–55] and the risk of testicular tumors [56] because it is a rare, low-penetrance allele (carrier frequency 2–3%) and thus accounts for a limited number of cases. The rs995030 SNP of the *KITLG* gene, which has been highly and consistently associated with risk of testicular cancer [21, 22, 45, 57] and is in strong linkage disequilibrium ($r^2 > 0.8$) with other susceptibility SNPs [20, 22, 57] was selected for the present analyses.

Our results give further support to the existence of a strong link between *KITLG* and the risk of testicular cancer, but the variant that we analyzed did not modify the association between the number of children and the risk of testicular cancer, thus sustaining the conclusion of a previous study, which was based on a different indicator of male fertility, i.e. total sperm count [45].

Although our study has the strength of using multiple indicators to assess fertility, it has also some relevant limitations. First, our response rate was low, even if it was in line with most previous studies on testicular cancer. It should be noted, however, that our results on well-recognized risk factors for testicular cancer (including cryptorchidism and sibship size), are consistent with the literature. Although it is possible that non-response was driven particularly by fertility status, the lack of evidence of non-response bias for recognized risk factors is reassuring. Second, our analyses are based on self-reported information, with no clinical data available to confirm fertility status. However, this is unavoidable in case-control studies when a lag-time between fertility assessment and the diagnosis of testicular cancer is considered. Even in cohort studies the prospective collection of semen samples is feasible only in specific subgroups of the population (e.g. subjects with fertility problems, semen donors, etc. . .). Furthermore, the self-reported number of children fathered by a man is a crude indicator of fertility status. However, we think that any misclassification that could have been introduced by this indicator would be non-differential between cases and controls. Finally, some of the associations in our study had large CIs; thus, although we can draw conclusions as to the direction of the associations and the overall consistency, inference based on the single estimates should be carried out with caution.

Conclusions

Our study supports previously reported inverse associations between testicular cancer and number of children and sibship size. However, our findings did not reveal an association between duration of attempt to conceive or use of assisted reproduction techniques and subsequent incidence of testicular cancer. The role of infertility, and the involved mechanisms, in testicular carcinogenesis remains to be elucidated.

Supporting Information

S1 Table. Association between indicators of fertility and risk of testicular cancer (restricted to nonseminoma subtype). Only cases with nonseminoma subtype and corresponding control subjects were included.

(PDF)

S2 Table. Association between indicators of fertility and risk of testicular cancer (restricted to seminoma subtype). Only cases with seminoma subtype and corresponding control subjects were included.

(PDF)

S3 Table. p-value for interaction between indicators of fertility and histological type (seminomas vs. nonseminomas) by comparing models with and without interaction by likelihood ratio test.

(PDF)

Acknowledgments

The authors thank the faculty and the students of the Master in Epidemiology, University of Turin, Italy, for feedback and comments on this work.

Author Contributions

Conceptualization: LR FM AGT.

Data curation: LC PL.

Formal analysis: CG NRR DZ.

Funding acquisition: LR NRR FM.

Investigation: LR CG NRR.

Methodology: LR CG AGT DZ NS FM VF.

Project administration: LR.

Resources: LR LC PL.

Supervision: LR.

Visualization: CG NRR.

Writing – original draft: LR CG.

Writing – review & editing: LR CG DZ MM AGT VF FM LC PL NS.

References

1. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. *Eur Urol*. 2011; 60: 374–9. doi: [10.1016/j.eururo.2011.05.004](https://doi.org/10.1016/j.eururo.2011.05.004) PMID: [21612857](https://pubmed.ncbi.nlm.nih.gov/21612857/)
2. Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of testicular germ cell tumors in the United States. *Andrology*. 2015; 3: 13–8. doi: [10.1111/andr.288](https://doi.org/10.1111/andr.288) PMID: [25331158](https://pubmed.ncbi.nlm.nih.gov/25331158/)
3. Bray F, Richiardi L, Ekblom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. *Int J Cancer*. 2006; 118: 3099–111. doi: [10.1002/ijc.21747](https://doi.org/10.1002/ijc.21747) PMID: [16395710](https://pubmed.ncbi.nlm.nih.gov/16395710/)
4. McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. *Nat Rev Urol*. 2012; 9: 339–49. doi: [10.1038/nrurol.2012.61](https://doi.org/10.1038/nrurol.2012.61) PMID: [22508459](https://pubmed.ncbi.nlm.nih.gov/22508459/)
5. Jacobsen R, Bostofte E, Engholm G, Hansen J, Skakkebaek NE, Møller H. Fertility and offspring sex ratio of men who develop testicular cancer: a record linkage study. *Hum Reprod*. 2000; 15: 1958–61. PMID: [10966994](https://pubmed.ncbi.nlm.nih.gov/10966994/)
6. Fosså SD, Kravdal O. Fertility in Norwegian testicular cancer patients. *Br J Cancer*. 2000; 82: 737–41. doi: [10.1054/bjoc.1999.0989](https://doi.org/10.1054/bjoc.1999.0989) PMID: [10682691](https://pubmed.ncbi.nlm.nih.gov/10682691/)
7. Richiardi L, Akre O, Montgomery SM, Lambe M, Kvist U, Ekblom A. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. *J Natl Cancer Inst*. 2004; 96: 145–7. PMID: [14734704](https://pubmed.ncbi.nlm.nih.gov/14734704/)
8. Møller H, Skakkebaek NE. Risk of testicular cancer in subfertile men: case-control study. *BMJ*. 1999; 318: 559–62. PMID: [10037628](https://pubmed.ncbi.nlm.nih.gov/10037628/)
9. Baker JA, Buck GM, Vena JE, Moysich KB. Fertility patterns prior to testicular cancer diagnosis. *Cancer Causes Control*. 2005; 16: 295–9. doi: [10.1007/s10552-004-4024-2](https://doi.org/10.1007/s10552-004-4024-2) PMID: [15947881](https://pubmed.ncbi.nlm.nih.gov/15947881/)
10. Doria-Rose P, Biggs ML, Weiss NS. Subfertility and the Risk of Testicular Germ Cell Tumors (United States). *Cancer Causes Control*. 2005; 5: 651–656.
11. Richiardi L, Akre O, Lambe M, Granath F, Montgomery SM, Ekblom A. Birth order, sibship size, and risk for germ-cell testicular cancer. *Epidemiology*. 2004; 15: 323–9. PMID: [15097013](https://pubmed.ncbi.nlm.nih.gov/15097013/)
12. Aschim EL, Haugen TB, Tretli S, Grotmol T. Subfertility among parents of men diagnosed with testicular cancer. *Int J Androl*. 2008; 31: 588–94. doi: [10.1111/j.1365-2605.2007.00813.x](https://doi.org/10.1111/j.1365-2605.2007.00813.x) PMID: [17822418](https://pubmed.ncbi.nlm.nih.gov/17822418/)
13. Cook MB, Akre O, Forman D, Madigan MP, Richiardi L, McGlynn KA. A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer—experiences of the mother. *Int J Epidemiol*. 2009; 38: 1532–42. doi: [10.1093/ije/dyp287](https://doi.org/10.1093/ije/dyp287) PMID: [19776243](https://pubmed.ncbi.nlm.nih.gov/19776243/)
14. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. *BMJ*. 2000b; 321: 789–92.
15. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. *J Urol*. 2005; 174: 1819–22. doi: [10.1097/01.ju.0000177491.98461.aa](https://doi.org/10.1097/01.ju.0000177491.98461.aa) PMID: [16217294](https://pubmed.ncbi.nlm.nih.gov/16217294/)
16. Walsh TJ, Croughan MS, Schembri M, Chan JM, Turek PJ. Increased risk of testicular germ cell cancer among infertile men. *Arch Intern Med*. 2009; 169: 351–6. doi: [10.1001/archinternmed.2008.562](https://doi.org/10.1001/archinternmed.2008.562) PMID: [19237718](https://pubmed.ncbi.nlm.nih.gov/19237718/)
17. Banz-Jansen C, Nikorowitsch C, Drechsler T, Felberbaum R, Schmutzler A, Diedrich K, et al. Incidence of testicular malignancies and correlation to risk factors in a TESE population of subfertile men. *Arch Gynecol Obstet*. 2012; 285: 247–53. doi: [10.1007/s00404-011-1938-2](https://doi.org/10.1007/s00404-011-1938-2) PMID: [21643980](https://pubmed.ncbi.nlm.nih.gov/21643980/)
18. Eisenberg ML, Li S, Brooks JD, Cullen MR, Baker LC. Increased risk of cancer in infertile men: analysis of U.S. claims data. *J Urol*. 2015; 193: 1596–601. doi: [10.1016/j.juro.2014.11.080](https://doi.org/10.1016/j.juro.2014.11.080) PMID: [25463997](https://pubmed.ncbi.nlm.nih.gov/25463997/)
19. Hanson HA, Anderson RE, Aston KI, Carrell DT, Smith KR, Hotaling JM. Subfertility increases risk of testicular cancer: evidence from population-based semen samples. *Fertil Steril*. 2016; 105: 322–8.e1. doi: [10.1016/j.fertnstert.2015.10.027](https://doi.org/10.1016/j.fertnstert.2015.10.027) PMID: [26604070](https://pubmed.ncbi.nlm.nih.gov/26604070/)
20. Kratz CP, Greene MH, Bratslavsky G, Shi J. A stratified genetic risk assessment for testicular cancer. *Int J Androl*. 2011; 34: 98–102.
21. Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, et al. A genome-wide association study of testicular germ cell tumor. *Nat Genet*. 2009; 41: 807–10. doi: [10.1038/ng.394](https://doi.org/10.1038/ng.394) PMID: [19483681](https://pubmed.ncbi.nlm.nih.gov/19483681/)
22. Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. *Nat Genet*. 2009; 41: 811–5. doi: [10.1038/ng.393](https://doi.org/10.1038/ng.393) PMID: [19483682](https://pubmed.ncbi.nlm.nih.gov/19483682/)
23. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. *Nat Genet*. 2010; 42: 604–7. doi: [10.1038/ng.607](https://doi.org/10.1038/ng.607) PMID: [20543847](https://pubmed.ncbi.nlm.nih.gov/20543847/)

24. Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li M, Ciosek SL, et al. A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. *Hum Mol Genet.* 2011; 20: 3109–17. doi: [10.1093/hmg/ddr207](https://doi.org/10.1093/hmg/ddr207) PMID: [21551455](https://pubmed.ncbi.nlm.nih.gov/21551455/)
25. Chung CC, Kanetsky PA, Wang Z, Hildebrandt MA, Koster R, Skotheim RI, et al. Meta-analysis identifies four new loci associated with testicular germ cell tumor. *Nat Genet.* 2013; 45: 680–5. doi: [10.1038/ng.2634](https://doi.org/10.1038/ng.2634) PMID: [23666239](https://pubmed.ncbi.nlm.nih.gov/23666239/)
26. Andreassen KE, Kristiansen W, Karlsson R, Aschim EL, Dahl O, Fosså SD, et al. Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. *Hum Reprod.* 2013; 28: 1995–2002. doi: [10.1093/humrep/det127](https://doi.org/10.1093/humrep/det127) PMID: [23639623](https://pubmed.ncbi.nlm.nih.gov/23639623/)
27. Ruark E, Seal S, McDonald H, Zhang F, Elliot A, Lau K, et al. Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. *Nat Genet.* 2013; 45: 686–9. doi: [10.1038/ng.2635](https://doi.org/10.1038/ng.2635) PMID: [23666240](https://pubmed.ncbi.nlm.nih.gov/23666240/)
28. Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MA, et al. Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. *Hum Mol Genet.* 2013; 22: 222748–53.
29. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. *Am J Pathol.* 1999; 154: 1643–1647. doi: [10.1016/S0002-9440\(10\)65419-3](https://doi.org/10.1016/S0002-9440(10)65419-3) PMID: [10362788](https://pubmed.ncbi.nlm.nih.gov/10362788/)
30. Looijenga LH, de Leeuw H, van Oorschot M, Van Gurp RJ, Stoop H, Gillis AJ, et al. Stem cell factor receptor (c-KIT) codon 816 transversions predict development of bilateral testicular germ cell tumors. *Cancer Res.* 2003; 63: 7674–7678 PMID: [14633689](https://pubmed.ncbi.nlm.nih.gov/14633689/)
31. Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, et al. Somatic mutations of KIT in familial testicular germ cell tumours. *Br J Cancer.* 2004; 90: 2397–2401. doi: [10.1038/sj.bjc.6601880](https://doi.org/10.1038/sj.bjc.6601880) PMID: [15150569](https://pubmed.ncbi.nlm.nih.gov/15150569/)
32. Coffey J, Linger R, Pugh J, Dudakia D, Sokal M, Easton DF, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. *Genes Chromosomes Cancer.* 2008; 47: 34–42. doi: [10.1002/gcc.20503](https://doi.org/10.1002/gcc.20503) PMID: [17943970](https://pubmed.ncbi.nlm.nih.gov/17943970/)
33. Mirabello L, Kratz CP, Savage SA, Greene MH. Promoter methylation of candidate genes associated with familial testicular cancer. *Int J Mol Epidemiol Genet.* 2012; 3: 213–27 PMID: [23050052](https://pubmed.ncbi.nlm.nih.gov/23050052/)
34. Boldajipour B, Raz E. What is left behind—quality control in germ cell migration. *Sci STKE.* 2007; 24: pe16.
35. Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. *Hum Reprod Update.* 1999; 5: 535–45. PMID: [10582791](https://pubmed.ncbi.nlm.nih.gov/10582791/)
36. Kissel H, Timokhina I, Hardy MP, Rothschild G, Tajima Y, Soares V, et al. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. *EMBO J.* 2000; 19: 1312–26. doi: [10.1093/emboj/19.6.1312](https://doi.org/10.1093/emboj/19.6.1312) PMID: [10716931](https://pubmed.ncbi.nlm.nih.gov/10716931/)
37. Guerif F, Cadoret V, Plat M, Magistrini M, Lansac J, Hochereau-De Reviers MT, et al. Characterization of the fertility of Kit haplodeficient male mice. *Int J Androl.* 2002; 25: 358–68. PMID: [12406368](https://pubmed.ncbi.nlm.nih.gov/12406368/)
38. Roskoski R Jr. Signaling by Kit protein-tyrosine kinase—the stem cell factor receptor. *Biochem Biophys Res Commun.* 2005; 337: 1–13. doi: [10.1016/j.bbrc.2005.08.055](https://doi.org/10.1016/j.bbrc.2005.08.055) PMID: [16129412](https://pubmed.ncbi.nlm.nih.gov/16129412/)
39. Fujisawa M, Kanzaki M, Okuda Y, Okada H, Arakawa S, Kamidono S. Stem cell factor in human seminal plasma as a marker for spermatogenesis. *Urology.* 1998; 51: 460–3. PMID: [9510353](https://pubmed.ncbi.nlm.nih.gov/9510353/)
40. Bialas M, Borczynska A, Rozwadowska N, Fiszer D, Kosicki W, Jedrzejczak P, et al. SCF and c-kit expression profiles in male individuals with normal and impaired spermatogenesis. *Andrologia.* 2010; 42: 83–91. doi: [10.1111/j.1439-0272.2009.00960.x](https://doi.org/10.1111/j.1439-0272.2009.00960.x) PMID: [20384797](https://pubmed.ncbi.nlm.nih.gov/20384797/)
41. Feng HL, Sandlow JI, Sparks AE, Sandra A, Zheng LJ. Decreased expression of the c-kit receptor is associated with increased apoptosis in subfertile human testes. *Fertil Steril.* 1999; 71: 85–9. PMID: [9935121](https://pubmed.ncbi.nlm.nih.gov/9935121/)
42. Kanatsu-Shinohara M, Miki H, Inoue K, Ogonuki N, Toyokuni S, Ogura A, et al. Germline niche transplantation restores fertility in infertile mice. *Hum Reprod.* 2005; 20: 2376–82. doi: [10.1093/humrep/dei096](https://doi.org/10.1093/humrep/dei096) PMID: [15919776](https://pubmed.ncbi.nlm.nih.gov/15919776/)
43. Galan JJ, De Felici M, Buch B, Rivero MC, Segura A, Royo JL, et al. Association of genetic markers within the KIT and KITLG genes with human male infertility. *Hum Reprod.* 2006; 21: 3185–92. doi: [10.1093/humrep/del313](https://doi.org/10.1093/humrep/del313) PMID: [16905672](https://pubmed.ncbi.nlm.nih.gov/16905672/)
44. Cheng P, Chen H, Liu SR, Pu XY, A ZC. SNPs in KIT and KITLG genes may be associated with oligospermia in Chinese population. *Biomarkers.* 2013; 18: 650–4. doi: [10.3109/1354750X.2013.838307](https://doi.org/10.3109/1354750X.2013.838307) PMID: [24083421](https://pubmed.ncbi.nlm.nih.gov/24083421/)

45. Ferlin A, Pengo M, Pizzol D, Carraro U, Frigo AC, Foresta C. Variants in KITLG predispose to testicular germ cell cancer independently from spermatogenic function. *Endocr Relat Cancer*. 2012; 19(1): 101–8. doi: [10.1530/ERC-11-0340](https://doi.org/10.1530/ERC-11-0340) PMID: [22194441](https://pubmed.ncbi.nlm.nih.gov/22194441/)
46. Richiardi L, Vizzini L, Pastore G, Segnan N, Gillio-Tos A, Fiano V, et al. Lifetime growth and risk of testicular cancer. *Int J Cancer*. 2014; 135: 695–701. doi: [10.1002/ijc.28688](https://doi.org/10.1002/ijc.28688) PMID: [24375202](https://pubmed.ncbi.nlm.nih.gov/24375202/)
47. Moirano G, Zugna D, Grasso C, Lista P, Ciuffreda L, Segnan N, et al. Baldness and testicular cancer: the EPSAM case-control study. *Andrology*. 2016; 4(2): 251–6. doi: [10.1111/andr.12148](https://doi.org/10.1111/andr.12148) PMID: [26941123](https://pubmed.ncbi.nlm.nih.gov/26941123/)
48. Dong SM, Pai SI, Rha SH, Hildesheim A, Kurman RJ, Schwartz PE, et al. Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2002; 11: 3–6 PMID: [11815394](https://pubmed.ncbi.nlm.nih.gov/11815394/)
49. United Kingdom Testicular Cancer Study Group. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. *BMJ*. 1994; 308: 1393–9. PMID: [7912596](https://pubmed.ncbi.nlm.nih.gov/7912596/)
50. Swerdlow AJ, Huttly SR, Smith PG. Testis cancer: post-natal hormonal factors, sexual behaviour and fertility. *Int J Cancer*. 1989; 45: 549–53.
51. Haughey BP, Graham S, Brasure J, Zielezny M, Sufrin G, Burnett WS. The epidemiology of testicular cancer in upstate New York. *Am J Epidemiol*. 1989; 130: 25–36 PMID: [2568087](https://pubmed.ncbi.nlm.nih.gov/2568087/)
52. Brown LM, Pottern LM, Hoover RN. Testicular cancer in young men: the search for causes of the epidemic increase in the United States. *J Epidemiol Community Health*. 1987; 41: 349–54. PMID: [2901454](https://pubmed.ncbi.nlm.nih.gov/2901454/)
53. Lynch M, Cram DS, Reilly A, O'Bryan MK, Baker HW, de Kretser DM, et al. The Y chromosome gr/gr subdeletion is associated with male infertility. *Mol Hum Reprod*. 2005; 11: 507–12. doi: [10.1093/molehr/gah191](https://doi.org/10.1093/molehr/gah191) PMID: [16123079](https://pubmed.ncbi.nlm.nih.gov/16123079/)
54. de Llanos M, Ballescà JL, Gázquez C, Margarit E, Oliva R. High frequency of gr/gr chromosome Y deletions in consecutive oligospermic ICSI candidates. *Hum Reprod*. 2005; 20: 216–20. doi: [10.1093/humrep/deh582](https://doi.org/10.1093/humrep/deh582) PMID: [15513974](https://pubmed.ncbi.nlm.nih.gov/15513974/)
55. Ferlin A, Tessari A, Ganz F, Marchina E, Barlati S, Garolla A, et al. Association of partial AZFc region deletions with spermatogenic impairment and male infertility. *J Med Genet*. 2005; 42: 209–13. doi: [10.1136/jmg.2004.025833](https://doi.org/10.1136/jmg.2004.025833) PMID: [15744033](https://pubmed.ncbi.nlm.nih.gov/15744033/)
56. Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. *Am J Hum Genet*. 2005; 77: 1034–43. doi: [10.1086/498455](https://doi.org/10.1086/498455) PMID: [16380914](https://pubmed.ncbi.nlm.nih.gov/16380914/)
57. Lessel D, Gamulin M, Kulis T, Toliat MR, Grgic M, Friedrich K, et al. Replication of genetic susceptibility loci for testicular germ cell cancer in the Croatian population. *Carcinogenesis*. 2012; 33: 1548–52. doi: [10.1093/carcin/bgs218](https://doi.org/10.1093/carcin/bgs218) PMID: [22745383](https://pubmed.ncbi.nlm.nih.gov/22745383/)